The US-based pharmaceutical technology business Gabri Labs has revealed plans to build a 10,000 square foot facility to manufacture medical devices close to home.
The international company has agreed to partner with Dubai Science Park to build a medical devices factory for an investment of AED 18 million (about Rs 37 crore), enhancing Dubai's appeal as a major centre for pharmaceutical and healthcare manufacturing.
With additional expansions anticipated by 2023, Gabri Lab's new facility will allow the pharmaceutical company to generate an initial volume of 12 million units annually. The Middle East and North Africa (MENA) area will receive distribution of the medical devices.
Gabri Labs has built a solid reputation for creating top-notch, cutting-edge over-the-counter medications and medical equipment in the therapeutic ENT and dermatology fields. The manufacture of numerous lines and a broad product portfolio, including the dermatological solutions line Curadem and the ENT brand OTOMAR, will be supported by the new facility in Dubai.